期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 99, 期 3, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2020.115282
关键词
Streptococcus pneumoniae; Serotype; PCV-10; PCV-13; Canada
资金
- Canadian Antimicrobial Resistance Alliance (CARA)
- National Microbiology Laboratory (NML)
- Merck Canada
- Pfizer Canada
- Shared Health
The study evaluated the coverage of invasive Streptococcus pneumoniae by pneumococcal conjugate vaccines (PCV)-10 and PCV-13 in Canada. The results showed that PCV-13 provided significantly greater coverage of S. pneumoniae serotypes and MDR isolates compared to PCV-10.
To assess the coverage of invasive Streptococcus pneumoniae by pneumococcal conjugate vaccines (PCV)-10 and PCV-13 across Canada. In total, 9166 invasive S. pneumoniae isolates were collected as part of the SAVE 2011 to 2017 study. Serotyping was performed by the Quellung reaction and antimicrobial susceptibility testing was performed using CLSI methods. The proportion of both PCV-10 and PCV-13 serotypes decreased significantly (P < 0.0001) from 2011 (26.7% and 48.0%, respectively) to 2017 (11.2% and 26.2%). For central, western, and eastern regions of Canada, PCV-13 provided significantly greater (P 0.0001) coverage at 33.7% (2060/6110), 23.0% (456/1985), and 36.3% (389/1071), respectively, compared to PCV-10 at 15.4% (939/ 6110), 10.1% (201/1985), and 15.8% (169/1071) coverage. PCV-13 provided significantly greater coverage (53.3%, 282/529) of multidrug-resistant (MDR) isolates (resistant to 3 antimicrobial classes) than PCV-10 (14.6%, 77/529, P < 0.0001). PCV-13 provided significantly greater coverage of invasive S. pneumoniae serotypes, as well as coverage of MDR isolates, than PCV-10. Crown Copyright (c) 2020 Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据